A Randomized, Double-blind, Multicenter Phase II Trial With Gemcitabine Plus Sorafenib Versus Gemcitabine Plus Placebo in Patients With Chemo-naive Advanced or Metastatic Adenocarcinoma of the Biliary Tract.

Trial Profile

A Randomized, Double-blind, Multicenter Phase II Trial With Gemcitabine Plus Sorafenib Versus Gemcitabine Plus Placebo in Patients With Chemo-naive Advanced or Metastatic Adenocarcinoma of the Biliary Tract.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Dec 2014

At a glance

  • Drugs Gemcitabine (Primary) ; Sorafenib (Primary)
  • Indications Biliary cancer; Gallbladder cancer
  • Focus Therapeutic Use
  • Acronyms GEMSO
  • Most Recent Events

    • 04 Aug 2012 Additional lead trial center identified as reported by European Clinical Trials Database.
    • 16 Nov 2011 Actual end date (20 Jul 2011) added as reported by European Clinical Trials Database.
    • 16 Nov 2011 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top